OTC Markets · Biotechnology · USD

BioAtla, Inc. (BCAB) Stock Analysis

BioAtla, Inc. (BCAB) is a Biotechnology stock listed on OTC Markets and quoted in US Dollar.

Last Updated: October 21, 2026

BCAB

$1.45

+$0.12 (+9.02%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCAB with… →

BCAB Key Statistics

As of Oct 21, 2026

Trading

Open: $1.26
Previous Close: $1.33
Day's Range: 1.26–1.45
52-Week Range: 1.07–71.50
Volume: 1.28K
Beta: 0.63

Valuation

Market Cap: $2.22M
P/E Ratio: unprofitable
P/S ratio: 0.26
EPS (ttm): −25.23

Financials (FY)

Revenue (FY): $2.00M−81.82%
Net Income (FY): −$59.61M
Shares Outstanding: 1.67M
1-Year Return: −95.80%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 57.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BCAB closed at $1.45, −95.80% over 1 year.

BioAtla, Inc. (BCAB) has a market capitalization of $2.22M.

In fiscal 2025, BCAB reported revenue of $2.00M.

BCAB Stock Return by Calendar Year

BioAtla, Inc. (BCAB) return since Dec 2020: what $10,000 became

1 year: $10,000 $420; −95.80%
5 years: $10,000 $10; −99.90%
Since Dec 2020: $10,000 $9; −99.91%

If you had invested $10,000 in BioAtla, Inc. (BCAB) at the close on December 16, 2020, the earliest close on record here, it would have been worth $9 at the close on October 21, 2026: −99.91% in total, −69.68% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+9.64%−42.28%−57.97%−70.18%−75.98%−3.89%−94.89%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−94.89%
2025	−3.89%
2024	−75.98%
2023	−70.18%
2022	−57.97%
2021	−42.28%
2020 (partial year)	+9.64%

As of October 21, 2026.

BCAB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$2.00M	−$59.61M	−2,980.4%
2024	$11.00M	−$69.78M	−634.3%
2023	$0.00	−$123.46M	—
2022	$0.00	−$106.48M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$2.00M	—	−$59.31M	−$59.61M	−2,980.4%
2024	$11.00M	—	−$73.94M	−$69.78M	−634.3%
2023	$0.00	—	−$129.69M	−$123.46M	—
2022	$0.00	—	−$108.14M	−$106.48M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BCAB Valuation vs Biotechnology Median

Median of 608 stocks

Metric	BCAB	Biotechnology median	vs median
P/S ratio	0.26	13.30	0.0x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

The market values BioAtla, Inc. (BCAB) at $2.22M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 41.

The 52-week range on file runs from $1.07 to $71.50. BCAB last closed at $1.45 on October 21, 2026. That is +$0.12 (+9.02%) against the previous close. The latest close sits 35.51% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.00M. That is −81.82% against the prior fiscal year, when revenue was $11.00M. The same year closed with a net loss of $59.61M. Earnings per share on a trailing basis come to −25.23.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $2.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.26 times revenue. On price-to-sales that is 0 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −95.80%. Measured over 5 years, that is −74.83% a year compounded. The reported beta is 0.63. Daily returns over the trailing 5 years annualize to a volatility of 128.71%.

Growth & Income

No dividend is on file for BCAB.

So far in 2026 the total return is −94.89%. Across the complete calendar years on file, 2025 returned −3.89% and 2024 returned −75.98%. Of the 5 complete calendar years on file, 0 finished higher.

Peer Comparison

BioAtla, Inc. (BCAB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
BioAtla, Inc.	BCAB	$2.22M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. BioAtla, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About BioAtla, Inc.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Visit website →